NMN has been recognized as a cosmetic ingredient for its firmness and luster, and it is thought that supplementing NMN can improve the condition of the skin. Effepharm is applying for a patent while conducting UV tests on the skin with NMN. We plan to publish an SCI treatise in the future.
Alzheimer’s disease is caused by the deposition of amyloid β peptide (Aβ). NMN reduced the accumulation of ROS in hippocampal sections of amyloid β peptide by restoring NAD + and ATP. Studies have shown that cognitive function in AD model mice has been restored.
Research studies have shown that NMN has the potential to prevent local ischemia. IPC stimulates SIRT1 and Sirt1 supports the delivery of blood throughout the body as a NAD + -dependent protein deacetylase. By activating Sirt1, NMN protects the heart and prevents ischemia and reperfusion.
Having healthy and active mitochondria makes you less susceptible to neurodegenerative diseases. NMN is likely to help prevent neurodegenerative diseases by increasing NAD + levels and increasing mitochondrial activity levels.
NMN works on the metabolism of adipose tissue and has the effect of burning the fat accumulated in the body. In a study, NMN intake improved insulin secretion, increased adiponectin, and showed a significant decrease in free fatty acids (FFA).
NAD + levels decrease with age. Studies have shown that NMN is enzymatically converted to NAD. When NMN activates the sirtuin gene, NAD + increases, which can be expected to improve physical function and suppress aging.
Uthever® NMN 's strengths
With so many scientific reports on animals, Effepharm decided to conduct our own clinical study on Uthever®. Our clinical study would start from:
(1) Safety assessment (2) Anti-aging (3) Boosting energy and increasing endurance
The clinical study on Uthever® is registered in the US and WHO’s official clinical registry system and displayed on the websites to the public.
Title: Evaluate the Efficacy and Safety of Uthever NMN(Nicotinamide Mononucleotide, a Form of Vitamin B3)
Official Title: A Multicentre, Randomized, Double-Blind, Parallel Design, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Uthever® (NMN), an Orally Administered Supplementation in Middle-Aged and Older Adults.
US register ID: NCT04228640
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A Multicenter, Randomized, Double-Blind, Placebo-Controlled
Primary Purpose: Prevention
To assess its safety, physical examination, blood biochemistry test, BMI, and HOMA will be performed at baseline and end of the study. Blood cellular NAD+ and NADH concentration in serum will de determined to confirm its ability to increase NAD levels in the human body.
Effepharm is proud to be the first and the only NMN Manufacturer in the world to conduct clinical trials. The clinical study on Uthever® is the largest scale in the world according to WHO’s the clinical database.
UTHEVER’s clinical trial report has been published on the frontier in aging. : The rise in the levels of NAD+/NADH at day 30 and day 60 illustrated the potential of Uthever to raise the levels of NAD+ in the cells, which is linked to higher energy levels and an anti-aging effect. Increased sensitivity to insulin has also been linked to antiaging. There was no noteworthy change in HOMA score, in the UTHEVER group whereas there was a noteworthy rise in the placebo group, demonstrating the anti-aging effect of Uthever as in its absence, the parameters worsened
Xem thêm chi tiết về KCARE HEALTH SDN BHD
